Clinical Trial Search

Primary: Proportion of Subjects Who Completed Colorectal Cancer (CRC) Screening Within 6 Months (Trial - Age Group 50-75) — 598; 192 Participants

Primary: Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy — 34; 11 Participants

Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004

Primary: Number of Bowel Movements Per Day — 5.8; 2 bowel movements/day — p=0.008

Primary: Change in Global Myocardial Blood Flow in Response to Vasodilator — 0.05; -0.145 percentage change in CFR

Primary: Time of Labor — 850.4; 1016.6 Minutes

Primary: Likelihood of Any Colorectal Cancer (CRC) Screening (for Study-eligible Patients) — 11.8; 4.5 Percentage of participants

Primary: Number of Subjects With Major Adverse Cardiovascular Events — 170; 167 participants — p=0.91

Primary: Sensitivity for Colorectal Cancer — 79.2 Percent

Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult

Primary: Use of FOBT ColoCARE Home Kit — 14; 2; 14; 0 participants

Primary: To Evaluate Rate of Anastomotic Leaks Related to the Use of the ColonRing™ Device, at 1 Month

Primary: Number of CRT Non-responders Using 1) Clinical Composite Score (CCS) and 2) Site-specific Criteria for Determining CRT Response — 1061; 900 Participants

Primary: Ct Value (Ct Values From PCR Reaction) — 38.4; 44.3; 44.6 Ct

Primary: Feasibility Rate of a Combined Therapy — 18 Participants

Primary: The Number of Higher Risk Patients Evaluated Thoroughly for Abuse at Intervention vs. Control Sites — 128; 128 Participants — p=0.11

Primary: Colorectal Cancer Screening Rate — 333; 162 Participants

Primary: CRC Screening Completion Rates — 550; 751 Participants — p=0.05

Primary: Breast Cup Immobilization Device II (GCC 1047) Feasibility — 25 Participants

Primary: Incidence of Adverse Events of Interest Per 100 Participants-Years By Actual Treatment (Malignancy Rules) — 0.45; 0.65 no. of events per 100 participant-years

Primary: Morbidity — 88; 93; 93 participants

Primary: The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days. — 7; 20 participants

Primary: Overall Survival (OS) Time — 6.71 Months

Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents

Primary: C-reactive Protein Rate — 47.9; 81.0; 50.0; 79.5 percentage

Primary: Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding Events — 9.2; 6.4 No. of new events per 100 person-years

Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025

Primary: Specificity and Sensitivity CDSD-unaided and CDSD-aided Endoscopist Predictions of Diminutive Polyp Histology — 90.8; 90.7; 64.7; 59.5 percentage of polyps

Primary: Number of CR Sessions Completed Within 6 Months in Patients Randomized to HYCR vs. Patients Randomized to Traditional CBCR (Usual Care). — 28.7; 27.6 Number of cardiac…

Primary: Number of Paramedics/Combat Medics Who Accurately Identified the Cricothyroid Membrane on Standardized Patients of Different Sizes — 6; 7; NA; 8 Participants